Boston Scientific Standing Apart As A Rare Med-Tech Growth Story

1 day ago · Boston Scientific’s Farapulse is the early leader in the field, and it has driven some eye-popping numbers in recent quarters, with electrophysiology (or EP) growth of 177% in …

177%
OFF

Boston Scientific Standing Apart As A Rare Med-Tech Growth Story

2 weeks from now

1 day ago · Boston Scientific’s Farapulse is the early leader in the field, and it has driven some eye-popping numbers in recent quarters, with electrophysiology (or EP) growth of 177% in …

seekingalpha.com

13%
OFF

Boston Scientific: Why This MedTech Giant Isn't Slowing Down

2 weeks from now

Boston Scientific Raises the Bar With Upside Guidance The company expects net sales for the third quarter of 2024 to grow 13% to 15% year over year and adjusted EPS between 57 cents …

msn.com

$14.24
OFF

Boston Scientific Corporation (BSX): A Diversified MedTech Leader ...

2 weeks from now

Nov 1, 2024 · Boston Scientific's financial performance has been impressive, with the company reporting annual revenue of $14.24 billion in 2023 and a net income of $1.59 billion. The …

beyondspx.com

$16.19
OFF

Boston Scientific Is Investing $16.19B On Medtech. What …

2 weeks from now

Boston Scientific itself, with the FARAPULSE™ system, stands at the forefront due to its innovative use of non-thermal energy, which reduces the risk of damage to surrounding …

scitodate.com

8%
OFF

Boston Scientific (BSX): A Promising Medical Stock With Strong …

2 weeks from now

Nov 3, 2024 · The global market for medical devices, estimated to be worth $570 billion in 2022, is expected to increase at a compound annual growth rate (CAGR) of 5.8% from 2023 to 2032, …

yahoo.com

8%
OFF

Boston Scientific (BSX): A Promising Medical Stock With Strong

2 weeks from now

The global market for medical devices, estimated to be worth $570 billion in 2022, is expected to increase at a compound annual growth rate (CAGR) of 5.8% from 2023 to 2032, reaching over …

msn.com

13%
OFF

Boston Scientific: Why This MedTech Giant Isn’t Slowing Down

2 weeks from now

Sep 17, 2024 · Boston Scientific Raises the Bar With Upside Guidance The company expects net sales for the third quarter of 2024 to grow 13% to 15% year over year and adjusted EPS …

nasdaq.com

FAQs about Boston Scientific Standing Apart As A Rare Med-Tech Growth Story Coupon?

Is Boston Scientific (BSc) outperforming other med-tech companies?

Boston Scientific Corporation is outperforming its peers in the med-tech sector with exceptional growth driven by key products like Farapulse and Watchman. Farapulse and Watchman are well-appreciated drivers with significant upside, but other contributors like urology, endoscopy, and peripheral interventions offer attractive complementary growth. ...

Is Boston Scientific (BSX) a rare med-tech growth story?

Boston Scientific Standing Apart As A Rare Med-Tech Growth Story Jan. 14, 2025 2:52 PM ETBoston Scientific Corporation (BSX) StockABT, JNJ, MDT1 Like Stephen Simpson 20.14KFollowers Follow Play(14min) Summary ...

What's behind Boston Scientific's Success?

One of those behemoths is the 25-year-old Boston Scientific, which had sales of $3.5 billion in 2003 and is expected to exceed that in 2004. Behind the success is the company's U.S. launch of its Taxus drug-eluting stent, a revolutionary technology that is radically changing the cardiovascular field. ...

Is Boston Scientific the biggest-selling drug-eluting stent in industry history?

Boston Scientific has been a major player, too, with its Taxus drug-eluting stent having the potential to become the biggest-selling device in industry history. But as with many breakthroughs in the device industry, this one was years in the making and took a lot of foresight and planning. ...

What makes Boston Scientific different from MD&DI?

Like MD&DI, the growth of Boston Scientific also tells the story of the past 25 years in the device industry. The Hemashield woven graft (right) is used to repair or replace damaged arteries. Boston Scientific's chief predecessor company, Medi-tech, was a pioneer in developing the steerable catheter and the balloon catheter. ...

Will new device approvals drive Boston Scientific's future growth?

New device approvals next year are expected to drive Boston Scientific’s future growth. The Marlborough, Massachusetts-based company reported 11% revenue growth in the third quarter, leading CEO Mike Mahoney to tell investors on Thursday that “2023 is shaping up to be a great year, a good jumping-off point heading into 2024.” ...